Neuphoria Therapeutics Inc.
NEUP
$4.40
$0.184.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.65M | 15.66M | 662.70K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.65M | 15.66M | 662.70K | -- | -- |
| Cost of Revenue | -100.00 | -1.07M | -1.49M | -1.19M | -100.00 |
| Gross Profit | 15.65M | 16.73M | 2.15M | 1.19M | 100.00 |
| SG&A Expenses | 7.77M | 8.08M | 7.87M | 7.76M | 8.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.48M | 16.13M | 15.50M | 15.90M | 17.80M |
| Operating Income | -829.10K | -470.60K | -14.84M | -15.90M | -17.80M |
| Income Before Tax | -838.00K | 5.59M | -8.35M | -11.01M | -15.58M |
| Income Tax Expenses | -468.40K | -235.90K | -138.30K | -184.70K | -87.30K |
| Earnings from Continuing Operations | -0.37 | 5.83 | -8.21 | -10.82 | -15.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -369.60K | 5.83M | -8.21M | -10.82M | -15.49M |
| EBIT | -829.10K | -470.60K | -14.84M | -15.90M | -17.80M |
| EBITDA | -166.30K | 192.20K | -14.17M | -15.23M | -17.13M |
| EPS Basic | 0.65 | 1.96 | -7.42 | -11.50 | -11.50 |
| Normalized Basic EPS | 0.21 | -0.55 | -6.37 | -8.95 | -8.95 |
| EPS Diluted | 0.64 | 1.96 | -7.42 | -11.50 | -11.50 |
| Normalized Diluted EPS | 0.21 | -0.55 | -6.37 | -8.95 | -8.95 |
| Average Basic Shares Outstanding | 2.81B | 2.81B | 2.81B | 2.81B | 1.50B |
| Average Diluted Shares Outstanding | 2.81B | 2.81B | 2.81B | 2.81B | 1.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |